⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,122.41
−0.44%
Brent
$108.83
−0.36%
BTC
$82,488.09
+0.79%
ETH
$2,433.89
+1.19%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,122.41
−0.44%
Brent
$108.83
−0.36%
BTC
$82,488.09
+0.79%
ETH
$2,433.89
+1.19%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› BLTE
B
Belite Bio Inc
NAS:BLTE
Healthcare
nasdaq_composite
$154.16
+4.63%
At close
At close · Tue 20 Oct · ≈
AED 566.15
· Market cap
$6.02B
· Next earnings
Mon 9 Nov
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Belite Bio Inc · News · TradingHolo
BLTE news
Headlines tagged to this company
RE
Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Reuters · 33 h ago
SE
Belite Bio to uplist to Nasdaq Global Select Market
Seeking Alpha · 34 h ago
GL
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
GlobeNewswire · 34 h ago
DO
Belite Bio Price Target Maintained With a $245.00/Share by HC Wainwright & Co.
Dow Jones Newswires · 5 d ago
RE
Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Reuters · 6 d ago
TR
Belite Bio, Inc (BLTE) Files MAAs for Tinlarebant in UK, Switzerland, Singapore
TradingView · 6 d ago
GL
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
GlobeNewswire · 19 d ago
GL
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
globenewswire · 42 d ago
BE
Why Is Belite Bio Stock Soaring Friday?
benzinga · 46 d ago
GL
Belite Bio to Participate in Four Upcoming Investor Conferences
globenewswire · 49 d ago
SE
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript
Seeking Alpha · 68 d ago
MA
Belite Bio Q2 Earnings Call Highlights
MarketBeat · 68 d ago
GL
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
GlobeNewsWire · 69 d ago
GL
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
GlobeNewsWire · 70 d ago
GL
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
GlobeNewsWire · 76 d ago
End of the feed